- Home
- TNGX vs CDNA Comparison
TNGX vs CDNA Comparison
Compare TNGX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CDNA
- Stock Information
- Founded
- TNGX 2014
- CDNA 1998
- Country
- TNGX United States
- CDNA United States
- Employees
- TNGX N/A
- CDNA N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CDNA Medical Specialities
- Sector
- TNGX Health Care
- CDNA Health Care
- Exchange
- TNGX Nasdaq
- CDNA Nasdaq
- Market Cap
- TNGX 723.2M
- CDNA 712.2M
- IPO Year
- TNGX N/A
- CDNA 2014
- Fundamental
- Price
- TNGX $8.76
- CDNA $14.68
- Analyst Decision
- TNGX Strong Buy
- CDNA Buy
- Analyst Count
- TNGX 6
- CDNA 8
- Target Price
- TNGX $10.00
- CDNA $26.86
- AVG Volume (30 Days)
- TNGX 2.1M
- CDNA 1.1M
- Earning Date
- TNGX 11-06-2025
- CDNA 11-04-2025
- Dividend Yield
- TNGX N/A
- CDNA N/A
- EPS Growth
- TNGX N/A
- CDNA N/A
- EPS
- TNGX N/A
- CDNA 1.00
- Revenue
- TNGX $24,296,000.00
- CDNA $340,826,000.00
- Revenue This Year
- TNGX $20.42
- CDNA $12.73
- Revenue Next Year
- TNGX N/A
- CDNA $11.90
- P/E Ratio
- TNGX N/A
- CDNA $14.72
- Revenue Growth
- TNGX N/A
- CDNA 14.72
- 52 Week Low
- TNGX $1.03
- CDNA $10.96
- 52 Week High
- TNGX $9.70
- CDNA $26.37
- Technical
- Relative Strength Index (RSI)
- TNGX 58.17
- CDNA 51.01
- Support Level
- TNGX $8.85
- CDNA $14.39
- Resistance Level
- TNGX $9.31
- CDNA $15.58
- Average True Range (ATR)
- TNGX 0.56
- CDNA 0.59
- MACD
- TNGX 0.08
- CDNA -0.03
- Stochastic Oscillator
- TNGX 67.60
- CDNA 44.62
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.